End-of-day quote
Shanghai S.E.
06:00:00 2024-04-29 pm EDT
|
5-day change
|
1st Jan Change
|
13.7
CNY
|
+5.14%
|
|
+3.47%
|
-8.67%
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
29,701
|
32,706
|
52,058
|
29,075
|
24,169
|
22,075
|
-
|
-
|
Enterprise Value (EV)
1 |
29,701
|
32,706
|
52,058
|
29,075
|
24,169
|
22,075
|
22,075
|
22,075
|
P/E ratio
|
49.4
x
|
40.4
x
|
47.7
x
|
26.9
x
|
-125
x
|
24
x
|
14.3
x
|
13.4
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
12
x
|
11.2
x
|
14.1
x
|
7.83
x
|
6.15
x
|
5.05
x
|
3.64
x
|
3.24
x
|
EV / Revenue
|
12
x
|
11.2
x
|
14.1
x
|
7.83
x
|
6.15
x
|
5.05
x
|
3.64
x
|
3.24
x
|
EV / EBITDA
|
41.7
x
|
32
x
|
40.8
x
|
22.1
x
|
-
|
17.6
x
|
11.1
x
|
10.4
x
|
EV / FCF
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Price to Book
|
10
x
|
9.2
x
|
9.8
x
|
4.77
x
|
4.22
x
|
3.33
x
|
2.43
x
|
2.1
x
|
Nbr of stocks (in thousands)
|
1,573,132
|
1,573,368
|
1,611,324
|
1,611,717
|
1,611,291
|
1,611,291
|
-
|
-
|
Reference price
2 |
18.88
|
20.79
|
32.31
|
18.04
|
15.00
|
13.70
|
13.70
|
13.70
|
Announcement Date
|
4/29/20
|
4/26/21
|
4/26/22
|
4/27/23
|
4/26/24
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
2,470
|
2,915
|
3,687
|
3,713
|
3,931
|
4,373
|
6,071
|
6,819
|
EBITDA
1 |
712.6
|
1,021
|
1,275
|
1,313
|
-
|
1,251
|
1,985
|
2,117
|
EBIT
1 |
667.6
|
877
|
1,182
|
1,174
|
-294.7
|
1,031
|
1,733
|
1,855
|
Operating Margin
|
27.03%
|
30.09%
|
32.06%
|
31.61%
|
-7.5%
|
23.57%
|
28.55%
|
27.21%
|
Earnings before Tax (EBT)
1 |
680.4
|
914.6
|
1,204
|
1,185
|
-294.8
|
1,031
|
1,741
|
1,855
|
Net income
1 |
605
|
806.1
|
1,059
|
1,091
|
-189.4
|
922.8
|
1,545
|
1,652
|
Net margin
|
24.5%
|
27.66%
|
28.73%
|
29.38%
|
-4.82%
|
21.1%
|
25.46%
|
24.22%
|
EPS
2 |
0.3823
|
0.5148
|
0.6769
|
0.6700
|
-0.1200
|
0.5700
|
0.9575
|
1.025
|
Free Cash Flow
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
4/29/20
|
4/26/21
|
4/26/22
|
4/27/23
|
4/26/24
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
ROE (net income / shareholders' equity)
|
22.5%
|
24.5%
|
25.3%
|
18.8%
|
-3.17%
|
13.9%
|
16.9%
|
15.8%
|
ROA (Net income/ Total Assets)
|
-
|
-
|
-
|
-
|
-
|
11.2%
|
12.4%
|
-
|
Assets
1 |
-
|
-
|
-
|
-
|
-
|
8,239
|
12,462
|
-
|
Book Value Per Share
2 |
1.880
|
2.260
|
3.300
|
3.790
|
3.560
|
4.110
|
5.630
|
6.520
|
Cash Flow per Share
2 |
-0.5300
|
-0.3600
|
0.4200
|
0.3700
|
1.000
|
0.1400
|
0.3400
|
0.4400
|
Capex
1 |
115
|
294
|
440
|
470
|
419
|
452
|
493
|
570
|
Capex / Sales
|
4.66%
|
10.09%
|
11.94%
|
12.66%
|
10.66%
|
10.34%
|
8.12%
|
8.36%
|
Announcement Date
|
4/29/20
|
4/26/21
|
4/26/22
|
4/27/23
|
4/26/24
|
-
|
-
|
-
|
Last Close Price
13.7
CNY Average target price
16.32
CNY Spread / Average Target +19.09% Consensus |
1st Jan change
|
Capi.
|
---|
| -8.67% | 3.05B | | +26.08% | 662B | | +21.85% | 546B | | -4.77% | 359B | | +16.97% | 323B | | +5.69% | 290B | | +13.68% | 234B | | +3.65% | 198B | | -11.12% | 194B | | +8.08% | 167B |
Other Pharmaceuticals
|